Specifically, it has been shown that 1% to 11% of women on PD-1/PD-L1 inhibitors and up to 11% of those taking CTLA-4 inhibitors get hypophysitis, while 6% of women taking PD-1/PD-L1 inhibitors and 15% of those using CTLA-4 inhibitors report having hypothyroidism [35,36,37]. Here, CTLA4 is linked to hypophysitis.